Combined antipsychotic treatment involving clozapine and aripiprazole

Progress in Neuro-psychopharmacology & Biological Psychiatry
Susanne Englisch, Mathias Zink

Abstract

Treatment resistance is considered a challenging problem of antipsychotic pharmacotherapy. In such cases, combination approaches are commonly used, for instance the add-on of aripiprazole to clozapine. This review aims at giving an overview of the present knowledge on this strategy. We performed a keyword-based screening of databases (including November 2007) and evaluated the data in a systematic manner. The courses of 94 patients were reported in 11 publications. At a mean dosage of 20.5 mg/day, aripiprazole achieved clinical improvement of psychotic symptoms and facilitated a dose reduction of clozapine from 476.7 to 425.1 mg/day. In parallel, clozapine serum levels decreased from 611 to 523 ng/ml. No pharmacokinetic interactions were reported, and clozapine-induced side effects ameliorated. However, single cases of extrapyramidal side effects occurred. The combination of clozapine and aripiprazole follows a neurobiological rationale and appears to be effective and tolerable. The results of placebo-controlled trials might allow further insight into the benefits and risks of this strategy.

References

Jan 1, 1995·Schizophrenia Bulletin·R W Buchanan
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
Jul 8, 2000·Schizophrenia Bulletin·S A Chong, G Remington
Aug 25, 2000·Journal of Psychopharmacology·M R Bennett
May 11, 2001·Seminars in Neurology·K D Sethi
Feb 5, 2002·Schizophrenia Bulletin·P BuckleyJ Csernansky
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Mar 14, 2003·The Journal of Clinical Psychiatry·Neil S Kaye
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasAndreas Rabavilas
Apr 24, 2003·The Annals of Pharmacotherapy·Toya M Bowles, Gary M Levin
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Mar 27, 2004·The International Journal of Neuropsychopharmacology·Robin Emsley, Piet Oosthuizen
Jun 8, 2004·Human Psychopharmacology·M ZinkH Dressing
Sep 16, 2004·The Journal of Clinical Psychiatry·Sabina LimChandra Cooper
Dec 31, 2004·The American Journal of Psychiatry·Richard C JosiassenRita A Shaughnessy
Jan 27, 2005·The Journal of Clinical Psychiatry·S Tziporah CohenRonald Pies
Jan 29, 2005·The American Journal of Psychiatry·Harpreet S Duggal, Joseph Kithas
Feb 16, 2005·Clinical Neuropharmacology·Vassilis P KontaxakisGeorge N Christodoulou
Sep 21, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Vassilis P KontaxakisDimitris K Roukas
Nov 2, 2005·The Journal of Clinical Psychiatry·George I PapakostasAndrew A Nierenberg
Feb 3, 2006·The New England Journal of Medicine·William G HonerUNKNOWN Clozapine and Risperidone Enhancement (CARE) Study Group
May 2, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fábio Lopes Rocha, Cláudia Hara
May 4, 2006·The Journal of Clinical Psychiatry·Laura A ClarkeSaurabh Kaushik
Aug 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·H G El-SayehC E Adams
Nov 18, 2006·Journal of Clinical Psychopharmacology·Fatima Abu-TairNiels Bergemann
Dec 14, 2006·Clinical Drug Investigation·Marc ZiegenbeinStefan Kropp
Jan 1, 2003·Clinical Drug Investigation·Michael J ReinsteinLynne E Jones

❮ Previous
Next ❯

Citations

Nov 3, 2009·Journal of Child and Adolescent Psychopharmacology·Antonella Gagliano, Gabriele Masi
Jun 16, 2012·Neuropsychiatric Disease and Treatment·Nilufar Mossaheb, Rainer M Kaufmann
Jul 22, 2010·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Alessandra BenedettiGiovanni Battista Cassano
Dec 24, 2008·Expert Review of Neurotherapeutics·Leslie Citrome
Mar 31, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alessandro De RisioBruno Gentile
Mar 10, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hsing-Kang ChenChing-Han Shao
Jan 19, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·D DassaJ C Samuelian
Sep 22, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Bart Peters, Lieuwe de Haan
May 4, 2011·Acta Psychiatrica Scandinavica·J NielsenD Taylor
Sep 25, 2015·Journal of Child and Adolescent Psychopharmacology·Hatice GunesAyten Erdogan
Jan 26, 2011·Schizophrenia Research·Maria Rosaria A MuscatelloRocco A Zoccali
Oct 23, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yi-Hang ChiuMong-Liang Lu
Mar 31, 2012·General Hospital Psychiatry·Amaia López de TorreJuan Medrano
Apr 4, 2015·International Journal of Psychiatry in Medicine·Ping-Tao TsengWeilun Chung
Aug 1, 2009·Clinical Neuropharmacology·Susanne EnglischMathias Zink
Jan 7, 2010·Current Opinion in Psychiatry·Mathias ZinkAndreas Meyer-Lindenberg
Jul 3, 2019·Current Psychiatry Reports·Chloé Tezenas du MontcelBaptiste Pignon
Jun 8, 2013·Pharmacological Reports : PR·Anna SzotaAleksander Araszkiewicz
Dec 7, 2017·Journal of Clinical Psychopharmacology·Lindsay-Rose Dykema
Sep 16, 2020·Expert Opinion on Drug Metabolism & Toxicology·Jean-Michel Azorin, Nicolas Simon
Nov 23, 2011·Clinical Neuropharmacology·Sandra SchönfelderMathias Zink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
Fábio Lopes Rocha, Cláudia Hara
Progress in Neuro-psychopharmacology & Biological Psychiatry
Alessandro De RisioBruno Gentile
© 2022 Meta ULC. All rights reserved